These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38771996)

  • 1. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care.
    Balmaceda NB; Petrillo A; Krishnan M; Zhao JJ; Kim S; Klute KA; Sundar R
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431060. PubMed ID: 38771996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
    Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
    Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Immunotherapy in Esophagogastric Cancer.
    Jazieh K; Yoon H; Zhu M
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):599-616. PubMed ID: 38493074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives.
    Sewastjanow-Silva M; Yamashita K; Rosa Vicentini E; Hirschmann M; Pool Pizzi M; Trail AM; Waters RE; Rogers JE; Ajani JA
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1177-1181. PubMed ID: 36266061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectivity of targeted therapy and immunotherapy in patients with advanced metastatic and non-metastatic cancer of the esophagus and esophago-gastric junction.
    Valkema MJ; Mostert B; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Updates Surg; 2023 Feb; 75(2):313-323. PubMed ID: 35836094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions.
    Balmaceda NB; Kim SS
    J Gastrointest Cancer; 2024 Mar; 55(1):153-167. PubMed ID: 38127239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Immunotherapy in Advanced Gastroesophageal Cancer.
    Terrero G; Lockhart AC
    Curr Oncol Rep; 2020 Aug; 22(11):112. PubMed ID: 32803457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Top Gastric Cancer Articles from 2022 and 2023 to Inform Your Cancer Practice.
    Mullen JT
    Ann Surg Oncol; 2024 Jun; 31(6):3978-3983. PubMed ID: 38388931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
    Saeed A; Park R; Sun W
    J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dawn of precision medicine on gastric cancer.
    Ishii T; Kawazoe A; Shitara K
    Int J Clin Oncol; 2019 Jul; 24(7):779-788. PubMed ID: 30976939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
    Fong CY; Chau I
    Pharmacogenomics; 2021 Jul; 22(11):703-726. PubMed ID: 34120461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy Approaches Beyond PD-1 Inhibition: the Future of Cellular Therapy for Head and Neck Squamous Cell Carcinoma.
    Qureshi HA; Lee SM
    Curr Treat Options Oncol; 2019 Mar; 20(4):31. PubMed ID: 30874960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies.
    Chen M; Li C; Sun M; Li Y; Sun X
    Front Immunol; 2022; 13():1043517. PubMed ID: 36505480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives.
    Takahari D; Nakayama I
    Int J Clin Oncol; 2023 Nov; 28(11):1431-1441. PubMed ID: 37500970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.
    Murphy AG; Kelly RJ
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):485-498. PubMed ID: 28501089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies.
    Hall A; Brown SR; Mettu NB; Miller PC; Smyth EC; Nixon AB
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433640. PubMed ID: 38888966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.